427 related articles for article (PubMed ID: 27939230)
41. Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study.
Miura T; Izawa A; Motoki H; Miyashita Y; Kashima Y; Ebisawa S; Tomita T; Koyama J; Ikeda U
PLoS One; 2015; 10(6):e0127835. PubMed ID: 26083546
[TBL] [Abstract][Full Text] [Related]
42. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study.
Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Palmer G;
Am J Cardiol; 2004 Sep; 94(6):720-4. PubMed ID: 15374773
[TBL] [Abstract][Full Text] [Related]
43. Effect of Multifactorial Treatment Targets and Relative Importance of Hemoglobin A1c, Blood Pressure, and Low-Density Lipoprotein-Cholesterol on Cardiovascular Diseases in Chinese Primary Care Patients With Type 2 Diabetes Mellitus: A Population-Based Retrospective Cohort Study.
Wan EYF; Fung CSC; Yu EYT; Chin WY; Fong DYT; Chan AKC; Lam CLK
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862945
[TBL] [Abstract][Full Text] [Related]
44. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
45. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
[TBL] [Abstract][Full Text] [Related]
46. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
[TBL] [Abstract][Full Text] [Related]
47. Visit-to-Visit Blood Pressure Variability and Mortality and Cardiovascular Outcomes Among Older Adults: The Health, Aging, and Body Composition Study.
Wu C; Shlipak MG; Stawski RS; Peralta CA; Psaty BM; Harris TB; Satterfield S; Shiroma EJ; Newman AB; Odden MC;
Am J Hypertens; 2017 Feb; 30(2):151-158. PubMed ID: 27600581
[TBL] [Abstract][Full Text] [Related]
48. Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy.
Vishram JK; Dahlöf B; Devereux RB; Ibsen H; Kjeldsen SE; Lindholm LH; Mancia G; Okin PM; Rothwell PM; Wachtell K; Olsen MH
J Hypertens; 2015 Dec; 33(12):2422-30. PubMed ID: 26378687
[TBL] [Abstract][Full Text] [Related]
49. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
50. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] trials).
Frey P; Waters DD; DeMicco DA; Breazna A; Samuels L; Pipe A; Wun CC; Benowitz NL
Am J Cardiol; 2011 Jan; 107(2):145-50. PubMed ID: 21129718
[TBL] [Abstract][Full Text] [Related]
51. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological management of modifiable cardiovascular risk factors (blood pressure and lipids) following diagnosis of myocardial infarction, stroke and diabetes: comparison between population-based studies in Russia and Norway.
Cook S; Hopstock LA; Eggen AE; Bates K; Iakunchykova O; Kontsevaya A; McKee M; Schirmer H; Voevoda M; Kudryavtsev AV; Malyutina S; Leon DA
BMC Cardiovasc Disord; 2020 May; 20(1):234. PubMed ID: 32430002
[TBL] [Abstract][Full Text] [Related]
53. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes.
Deedwania PC; Pedersen TR; DeMicco DA; Breazna A; Betteridge DJ; Hitman GA; Durrington P; Neil A;
Int J Cardiol; 2016 Nov; 222():548-556. PubMed ID: 27513651
[TBL] [Abstract][Full Text] [Related]
54. Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.
Yan X; Li Y; Dong Y; Wu Y; Li J; Bian R; Hu D
Lipids Health Dis; 2019 Jan; 18(1):32. PubMed ID: 30696435
[TBL] [Abstract][Full Text] [Related]
55. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
56. Cardiovascular outcomes and their relationships to lipoprotein components in patients with and without chronic kidney disease: results from the IDEAL trial.
Holme I; Fayyad R; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Larsen ML; Lindahl C; Holdaas H; Pedersen TR;
J Intern Med; 2010 Jun; 267(6):567-75. PubMed ID: 20141566
[TBL] [Abstract][Full Text] [Related]
57. Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels.
Pischon T; Möhlig M; Hoffmann K; Spranger J; Weikert C; Willich SN; Pfeiffer AF; Boeing H
Eur J Epidemiol; 2007; 22(7):429-38. PubMed ID: 17557140
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
59. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
[TBL] [Abstract][Full Text] [Related]
60. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery.
Shah SJ; Waters DD; Barter P; Kastelein JJ; Shepherd J; Wenger NK; DeMicco DA; Breazna A; LaRosa JC
J Am Coll Cardiol; 2008 May; 51(20):1938-43. PubMed ID: 18482661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
